Ledyard National Bank lowered its holdings in Pfizer, Inc. (NYSE:PFE) by 0.2% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 412,665 shares of the biopharmaceutical company’s stock after selling 948 shares during the period. Pfizer makes up 2.0% of Ledyard National Bank’s holdings, making the stock its 3rd biggest holding. Ledyard National Bank’s holdings in Pfizer were worth $13,861,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in PFE. First Command Financial Services Inc. grew its holdings in shares of Pfizer by 3.9% in the first quarter. First Command Financial Services Inc. now owns 10,338 shares of the biopharmaceutical company’s stock valued at $354,000 after purchasing an additional 384 shares in the last quarter. Atria Investments LLC grew its holdings in shares of Pfizer by 17.6% in the first quarter. Atria Investments LLC now owns 193,374 shares of the biopharmaceutical company’s stock valued at $6,615,000 after purchasing an additional 28,945 shares in the last quarter. BLB&B Advisors LLC grew its holdings in shares of Pfizer by 0.5% in the first quarter. BLB&B Advisors LLC now owns 260,753 shares of the biopharmaceutical company’s stock valued at $8,920,000 after purchasing an additional 1,187 shares in the last quarter. Tompkins Financial Corp grew its holdings in shares of Pfizer by 23.3% in the first quarter. Tompkins Financial Corp now owns 113,660 shares of the biopharmaceutical company’s stock valued at $3,368,000 after purchasing an additional 21,504 shares in the last quarter. Finally, Norway Savings Bank grew its holdings in shares of Pfizer by 19.7% in the first quarter. Norway Savings Bank now owns 14,473 shares of the biopharmaceutical company’s stock valued at $495,000 after purchasing an additional 2,385 shares in the last quarter. Hedge funds and other institutional investors own 68.99% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Pfizer, Inc. (PFE) is Ledyard National Bank’s 3rd Largest Position” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.themarketsdaily.com/2017/10/11/pfizer-inc-pfe-is-ledyard-national-banks-3rd-largest-position.html.
In other news, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the transaction, the insider now directly owns 145,649 shares of the company’s stock, valued at $5,097,715. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $34.00, for a total value of $249,900.00. Following the transaction, the insider now directly owns 124,774 shares in the company, valued at $4,242,316. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock worth $15,813,961 over the last quarter. 0.06% of the stock is currently owned by company insiders.
A number of research analysts recently weighed in on PFE shares. Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Monday, July 17th. BMO Capital Markets upgraded shares of Pfizer from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $33.00 to $37.00 in a research note on Wednesday, August 2nd. UBS AG reiterated a “buy” rating and issued a $38.00 price target on shares of Pfizer in a research note on Monday, July 31st. ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. Finally, BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research note on Friday, June 23rd. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $38.21.
Shares of Pfizer, Inc. (NYSE PFE) traded down 0.047% during trading on Wednesday, reaching $36.383. 6,338,081 shares of the company’s stock traded hands. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $36.51. The company has a market capitalization of $60.12 billion, a price-to-earnings ratio of 26.557 and a beta of 1.00. The company has a 50 day moving average of $34.92 and a 200-day moving average of $33.71.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The company had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period last year, the business posted $0.64 earnings per share. Equities analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 3.52%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s payout ratio is 94.12%.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.